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ABSTRACT
The incidence of central nervous system (CNS) complications, their risk factors, and impact on outcome are
not well defined in recipients of allogeneic hematopoietic stem cell transplant (aHSCT). We reviewed the
medical records of 302 consecutive patients who underwent aHSCT for malignant and nonmalignant hema-
tologic diseases at Princess Margaret Hospital between 2002 and 2005. The cumulative incidences of all CNS
complications and posterior reversible encephalopathy syndrome (PRES) at days 100 and 365 were 18% (95%
confidence interval [CI]: 14-22) and 23% (95% CI: 19-29), and 6% (95% CI: 4-9) and 7% (95% CI: 5-11),
respectively. Seizures occurred in 37% of all CNS events in the first 100 days and 73% of PRES episodes.
Female gender and high-dose total-body irridiation (TBI) were identified as independent risk factors for CNS
complications in the first 100 days posttransplant. Survival at 1-year was significantly inferior in patients who
developed CNS complications within 100 days of transplant (28% [95% CI: 17-41] versus 72% [95% CI:
66-77]) and PRES (27% [95% CI: 10-47] versus 67% [95% CI: 62-73]) compared to those who did not (P <
.0001). Death from graft-versus-host disease (GVHD) was more common in patients with CNS complications
in the first 100 days (P  .006) and PRES (P  .01) compared to patients without complications.
© 2007 American Society for Blood and Marrow Transplantation
KEY WORDS
Allogeneic ● Stem cell transplant ● Neurologic ● PRES ● Survival ● Risk factors
f
a
A
p
t
s
c
t
p
a
t
s
INTRODUCTION
The manifestations, etiology, and time course of
entral nervous system (CNS) complications, espe-
ially posterior reversible encephalopathy syndrome
PRES), are not well characterized in adult allogeneic
ematopoietic stem cell transplant (aHSCT) recipi-
nts. aHSCT patients are at risk for CNS complica-
ions due to various regimen-related toxicities (RRT),
ytopenias, drug toxicities, infections, and graft-
ersus-host disease (GVHD). Previous studies de-
cribe an incidence of neurologic complications of 8%
o 42% in bone marrow transplant recipients [1-11].
his wide variation may be related to type of trans-
lant, deﬁnition of neurologic complications, popula-
ions examined, preparatory regimens, duration of (ollow-up, and study designs. Prospective studies in this
rea are inconclusive due to small sample size [1,10].
dditionally, these studies do not reﬂect current clinical
ractices such as increasing use of reduced intensity
ransplants, transplantation in older patients, and wide-
pread use of peripheral blood stem cells.
In most clinical studies [1-3,8], the most common
auses of CNS complications are cyclosporine neuro-
oxicity or metabolic disturbances, whereas in neuro-
athologic studies [12,13] cerebrovascular disorders
re the primary diagnosis. Various studies have iden-
iﬁed type of transplant, pretransplant disease risk
tatus, acute myeloid malignancy, greater than grade
I GVHD, cyclosporine, and total-body irradiation
TBI) as risk factors for neurologic complications
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D. Siegal et al.13702,3,11]. No studies have analyzed clinical risk factors
or PRES in this population. Moreover, previous stud-
es in this area are difﬁcult to interpret due to different
eﬁnitions of this complication [14-19]. No modiﬁ-
ble risk factors prior to stem cell transplantation have
een examined with regard to CNS complications or
RES. Intensity or type of treatment prior to trans-
lant may be an important factor for CNS complica-
ions given that some chemotherapies such as high-
ose ara-C (HiDAC) and ﬂudarabine are associated
ith CNS complications especially in older patients
nd those with renal impairment [20-24]. Moreover,
he impact of CNS complications on posttransplant
urvival is unclear due to conﬂicting results [1,2,7].
We retrospectively analyzed data on 302 patients
reated consecutively with aHSCT for malignant and
onmalignant hematologic disorders at Princess Mar-
aret Hospital (PMH). The main objectives of the study
ere to understand the spectrum of CNS complications,
specially PRES, in aHSCT recipients, and to identify
atient, disease, treatment prior to aHSCT, and trans-
lant-related risk factors for these complications.
ATIENTS AND METHODS
atients
We analyzed the clinical course of 302 consecutive
atients who underwent aHSCT for malignant and
onmalignant hematologic disorders at PMH (Uni-
ersity Health Network [UHN], Toronto, Ontario,
anada) between January 2002 and November 2005.
hese patients were identiﬁed from a prospective
ransplant database updated regularly for various
ransplant-related complications and events. Data on
atients, donors, disease, treatment prior to trans-
lant, and transplant-related factors were collected
rom the transplant database and computerized hos-
ital records. The study was approved by the Cancer
egistry Data Access Committee (CRDAC) and
HN Research Ethics Board.
onditioning Regimens, GVHD Prophylaxis,
nd Supportive Care
Patients received conditioning therapy according
o ongoing institutional protocols. The choice of in-
ensity of conditioning regimen was based on the
atient’s age, comorbidities, and underlying disease
ccording to transplant program policies. The inten-
ity of conditioning therapy was deﬁned as conven-
ional (myeloablative), reduced, or minimal. For he-
atologic malignancies, the conventional intensity
onditioning (CIC) protocols were: cytarabine (ara-C)
500 mg/m2)/high-dose cyclophosphamide (120 mg/
g) and TBI (500 cGy in a single fraction) [25], high-
ose cyclophosphamide (120-180 mg/kg) and high-
ose TBI (1200 cGy in 6 fractions) [26], and i.v./p.o. uusulphan (16 mg/kg p.o. or 12.8 mg/kg i.v.) and
yclophosphamide (120 mg/kg) [27]. The reduced-
ntensity conditioning (RIC) protocol included ﬂu-
arabine (120 mg/m2) and i.v. busulphan (6.4 mg/kg)
nd the minimal intensity conditioning (MIC) proto-
ol consisted of ﬂudarabine (125 mg/m2) and low-dose
BI (200 cGy) [28]. For patients with aplastic anemia,
IC consisted of a high-dose cyclophosphamide-
ased protocol (200 mg/kg) and MIC consisted of
udarabine (120 mg/m2) and low-dose cyclophospha-
ide (40 mg/kg). GVHD prophylaxis for CIC and
IC/MIC protocols were with cyclosporine and a
hort course of methotrexate [26], and cyclosporine
nd mycophenolate [29], respectively. Cyclosporine
rough levels were maintained between 200 and 400
g/mL. Supportive care was provided as described
reviously [28].
NS Complications
Data on all clinically signiﬁcant CNS complica-
ions in the ﬁrst year following aHSCT were collected
sing a case report form speciﬁcally designed for this
tudy. The following complications were deﬁned as
linically signiﬁcant: seizures, loss of vision in the
bsence of local pathology, altered level of conscious-
ess (ALOC), involuntary movements, ataxia, paresis,
ranial nerve palsies, speech impairment, and delir-
um. The etiology of CNS complications were deter-
ined by clinical, microbiologic, and radiologic char-
cteristics, and were broadly classiﬁed as focal white
atter abnormalities or PRES, metabolic encepha-
opathy (renal failure, liver failure, or electrolyte
mbalance), cerebrovascular (hemorrhage, ischemia/
nfarct), infectious (viral, fungal, bacterial, protozoal),
hrombotic thrombocytopenic pupura/hemolytic ure-
ic syndrome-like (TTP/HUS) and vasculitis. CNS
vents that occurred following relapsed disease were
ot included. Cyclosporine trough levels and serum
agnesium levels at the onset of CNS complications
ere obtained from computerized hospital records.
anagement of Patients with CNS Complications
CNS complications in the posttransplant period
uch as seizures, loss of vision, and ALOC were man-
ged by a deﬁned strategy of the Blood and Marrow
ransplant Program involving discontinuation of cy-
losporine and urgent brain imaging studies (MRI
nd/or CT). Other CNS complications were managed
ccording to clinical needs. If imaging studies revealed
vidence of focal white matter abnormalities or PRES,
yclosporine was discontinued. Serial imaging studies
ere conducted once per week until resolution of
RES changes. Upon resolution of these changes,
atients were switched to FK-506. If the complica-
ions recurred, calcineurin inhibitors were discontin-
ed and patients were given GVHD prophylaxis with
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CNS Complications in Allogeneic Transplant Recipients 1371ycophenolate mofetil (MMF) or at the discretion of
he attending physician. Some patients underwent ad-
itional investigations such as lumbar puncture and/or
lectroencephalogram (EEG) as clinically indicated.
he time from onset of CNS complication to ﬁrst
maging study was 12 hours in the majority (90%)
f patients with CNS complications in the ﬁrst 100
ays post-aHSCT.
maging Studies
All neuroimaging studies conducted following
NS events were reviewed by 2 neuroradiologists
linded to clinical histories, outcomes, and original
maging reports. All patients had magnetic resonance
MR) scans of the brain on a 1.5 Tesla scanner (GE
edical Systems, Milwaukee, WI) using an 8-channel
ead coil. The study included FLAIR, gradient echo,
nd diffusion sequences in addition to the usual spin
cho sequences. Gadolinium was given to most pa-
ients to exclude infectious complications. Noncon-
rast CT scans were done to exclude hemorrhage in 17
atients. Criteria for PRES included the presence on
igure 1. FLAIR axial images of brain show mild (A), moderate (B),
f 1, 2, and 3, respectively.LAIR images of conﬂuent subcortical white matter
esions with little or no adjacent cortical involvement
30,31]. The lesions were found to be occipital (uni-
ateral or bilateral), with or without frontal involve-
ent (unilateral or bilateral). Note was made of any
rainstem and cerebellar involvement. The following
rbitrary criteria were used to grade severity of PRES:
1) mild: size 2 cm, unilateral or bilateral occipital
ocation (Figure 1A); (2) moderate: size 2 cm with
ilateral occipital involvement (Figure 1B); (3) severe:
ilateral occipital lesions with unilateral/bilateral
rontal lesions, brainstem or cerebellar involvement,
r any hemorrhage (Figure 1C and D).
retransplant Treatment Intensity and Definitions
f Posttransplant Events
We arbitrarily deﬁned pretransplant treatment in-
ensity as: (1) mild: single-agent chemotherapy 6
onths, or minimally transfused (20 transfusions);
2) moderate: single-agent chemotherapy 6 months,
p to 2 cycles of intensive chemotherapy for acute
eukemia (AL), 1-2 lines of chemotherapy for lympho-
vere (C and D) forms of PRES corresponding with severity gradingand se
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D. Siegal et al.1372roliferative disorders (LPD), or moderate transfu-
ions (20-50); (3) heavy: 3-4 cycles of chemotherapy
or AL, 3-4 lines of chemotherapy for LPD, or heavily
ransfused (50); and (4) very heavy: 5 cycles of
hemotherapy for AL, 5 lines of chemotherapy for
PD, or previous autologous or allogeneic transplant.
HiDAC was deﬁned as 9 g/m2 of ara-C in 1
hemotherapy cycle. The majority of younger AML
atients (60 years) received HiDAC according to the
ancer and Leukemia Group B (CALGB) schedule
24]. Older AML patients received HiDAC as previ-
usly described [28]. Patients with relapsed or refrac-
ory acute myelogenous leukemia (AML) received
iDAC as part of the NOVE-HiDAC protocol [28].
ngraftment, acute and chronic GVHD (aGVHD,
GVHD), and severity of aGVDH and cGVHD were
eﬁned as previously described [28]. Overall survival
as calculated from the date of transplant to death or
ast follow-up.
tatistical Analysis
Results were reported as proportions and 95% CI.
he cumulative incidence of CNS complications and
RES was estimated with the Cmprsk package in the
software (The R Foundation, Vienna, Austria).
eath from any cause and relapse were treated as
ompeting risks [32]. The Kaplan-Meier method was
sed to estimate survival [33]. Multivariate analysis
as used to explore risk factors for CNS complica-
ions within the ﬁrst 100 days based on the logistic
egression method. The likelihood ratio test was used
o choose the multivariate model. Overall goodness of
t of the multivariate logistic regression model was
ssessed using the Hosmer and Lemeshow test. All
nalyses were performed with SAS 9.1 (SAS Institute,
ary, NC). A P-value.05 was considered signiﬁcant.
ESULTS
atient Characteristics
Patient, donor, disease, and treatment-related
haracteristics are shown in Table 1. Signiﬁcant neu-
ologic history prior to transplant was identiﬁed in 21
atients (7%) as history of seizures (n  5), CVA/TIA
n  4), and “other,” including CNS involvement by
rimary underlying disease (n  12).
ncidence and Manifestations of All CNS
omplications and PRES
All CNS complications. The cumulative incidence of
NS complications at days 30, 100, 180, and 365 was
% (95% CI: 7-13), 18% (95% CI: 14-22), 20% (95%
I: 16-25), and 23% (95% CI: 19-29), respectively
Figure 2). Within 100 days posttransplant, 52 pa-
ients developed 57 CNS events. Of the 250 patients
urviving 100 days, 22 developed 25 CNS events.able 1. Patient, Disease, and Treatment-Related Characteristics
Characteristics
Number of Patients
(n  302)
N (%)
edian age of recipients (range) 46 (18-71)
edian age of donors (range) 46 (11-76)
roportion of male patients (%) 59
iagnosis
AML/MDS 125 (42)
CML 39 (13)
ALL 37 (12)
NHL/CLL 53 (17)
AA 15 (5)
MF 16 (5)
Others 17 (6)
NS involvement of primary disease
Yes 12 (4)
No 290 (96)
isk of disease
Standard risk 87 (29)
High risk 215 (71)
isease status at transplant
CR1/CR2/CP1 158 (53)
Chemosensitive LPD 62 (20)
CP2/active/accelerated 32 (11)
Untreated/other 50 (16)
iDAC prior to transplant
None 176 (58)
1 course 29 (10)
2 courses 46 (15)
>3 courses 45 (15)
Missing 6 (2)
ludarabine anytime prior to
transplant conditioning
Yes 41 (14)
No 256 (85)
Missing 5 (1)
ranial irradiation prior to transplant
Yes 18 (6)
No 282 (93)
Missing 2 (1)
onditioning regimen
Conventional intensity 243 (81)
Reduced intensity 22 (7)
Minimal intensity 37 (12)
BI in conditioning regimen
None 89 (20)
Low dose (200-300 cGy) 40 (13)
Moderate dose (500 cGy) 48 (16)
High dose (1200 cGy) 125 (41)
VHD prophylaxis
CSA  MTX 234 (77)
CSA  MMF 59 (20)
Other 9 (3)
ype of graft
Bone marrow 89 (29)
Peripheral blood 213 (71)
LA match
Matched family donor 224 (74)
Mismatched family donor 26 (9)
Matched unrelated donor 52 (17)
ML indicates acute myeloid leukemia; MDS, myelodysplastic syn-
drome; CML, chronic myelogenous leukemia; ALL, acute lym-
phocytic leukemia; NHL, Non-Hodgkin’s lymphoma; CLL,
chronic lymphocytic leukemia; AA, aplastic anemia; MF, myelo-
ﬁbrosis; CR1, complete remission 1; CR2, complete remission 2;
HiDAC, high-dose ara-c; LPD, lymphoproliferative disorder;
CP1, chronic phase 1; CP2, chronic phase 2; TBI, total body
irradiation; GVHD, graft-versus-host disease; CSA, cyclospor-
ine; MTX, methotrexate; MMF, mycophenolate mofetil; HLA,
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CNS Complications in Allogeneic Transplant Recipients 1373The etiology of CNS events is described in Table 2.
ithin 100 days of transplant, manifestations were
eizures (n  21), visual disturbance (n  14), ALOC
n  7), delirium (n  18), and other (n  7). From
01 days onward, manifestations were seizures (n  6),
isual disturbance (n  7), ALOC (n  2), delirium
n  17), and other (n  8).
PRES. There were a total of 22 episodes of PRES
n 21 patients (1 patient had 2 episodes of PRES). The
umulative incidence of PRES at 30, 100, 180, and
65 days was 4% (95% CI: 2-7), 6% (95% CI: 4-9),
% (95% CI: 4-10), and 7% (95% CI: 5-11), respec-
igure 2. The cumulative incidences of all CNS complications and
%, 6%, 7%, and 7%, respectively.
able 2. Etiology of CNS Complications
Etiology
Number of CNS
Events 0-100 Days
Posttransplant
(n  57)
N (%)
Number of CNS Events
101 Days-1 Year
Posttransplant
(n  25)
N (%)
ocal white matter
abnormalities 29 (51) 6 (24)
PRES 18 4
Other 11 2
etabolic 8 (14) 2 (8)
Hepatic 7 2
Renal 1 0
erebrovascular 1 (2) 0
nfectious 2 (4) 4 (16)
Bacterial 0 1
Viral 0 2
Fungal 2 0
Brain abscess of
unknown
origin 0 1
TP-like 1 (2) 1 (4)
ther 5 (9) 9 (36)
ndetermined 11 (19) 3 (12)
RES indicates posterior reversible encephalopathy syndrome;
0TTP, thrombocytopenic thrombotic purpura.ively (Figure 2). The median number of days to onset
f PRES was 30 (range: 8-226) with 82% (n  18) of
ases occurring within 100 days, and 18% (n  4)
ccurring between 101 and 365 days posttransplant.
The presenting manifestations of PRES were sei-
ures (n  16), visual disturbance (n  6), delirium
n  3), and ALOC (n  2). Imaging ﬁndings associ-
ted with PRES were most apparent on the FLAIR
equence. Findings included diffusion abnormality
n  1), conﬂuent white matter subcortical FLAIR
bnormality (n 20), infarct (n 1), and hemorrhage
n  1). PRES severity was classiﬁed as mild (n  5),
oderate (n 8), and severe (n 9). Gadolinium was
ot useful in the diagnosis of PRES. None of the
LAIR lesions were enhanced with contrast.
Out of 5 patients with a history of seizure prior to
ransplant, 2 developed seizures post-aHSCT. One
atient had PRES according to the described criteria
nd the other patient had other focal white matter
bnormalities. Seizures due to PRES occurred in
patient with a history of a syncopal episode prior to
ransplant. Of 12 patients with CNS involvement of
rimary disease prior to transplant, 17% (n  2)
xperienced CNS complications. One patient devel-
ped PRES and the other patient had delirium of
ndetermined origin.
isk Factors
Risk factors for CNS complications in the ﬁrst 100
ays were analyzed by univariate analysis as shown in
able 3. Signiﬁcant factors associated with develop-
ent of CNS complications included imatinib any-
ime prior to transplant (P .02), no ﬂudarabine prior
o transplant conditioning (P  .04), CIC regimen
P .006), high-dose TBI in conditioning regimen (P
at days 30, 100, 180, and 365 were 9%, 18%, 20%, and 23%, andPRES03), and cyclosporine plus methotrexate as GVHDpro-
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D. Siegal et al.1374able 3. Risk Factors for Development of CNS Complications within 100 Days Posttransplant
Characteristics
Patients with CNS
Complications (n  52)
Patients without CNS
Complications (n  250) P-Value
edian age of recipients (range) 46 (20-67) 45 (18-71) .94
ge of recipients (years) .42
<40 22 83
40-59 26 140
>60 4 27
edian age of donors (range) 47 (12-76) 45 (11-73) .29
ender .08
Male 25 153
Female 27 97
iagnosis .20
AML/MDS 17 108
CML 8 31
ALL 8 29
NHL/CLL 5 48
AA 3 12
MF 5 11
Others 6 11
NS involvement of primary disease .96
Yes 2 10
No 50 240
isk of disease .51
Standard 13 74
High 39 176
reatment intensity prior to transplant .76
None 3 21
Minimal 9 31
Moderate 15 61
Heavy 15 80
Very heavy 10 57
iDAC prior to transplant .53
None 31 145
1 course 6 23
2 course 5 41
>3 courses 10 35
Missing 0 6
ludarabine anytime prior to transplant conditioning .04
Yes 2 39
No 50 206
Missing 0 5
matinib anytime prior to transplant .02
Yes* 12 28
No 40 222
ranial irradiation prior to transplant .39
Yes 5 13
No 47 235
Missing 0 2
onditioning regimen .006
Conventional intensity 49 194
Reduced  minimal intensity 3 56
BI in conditioning regimen .003
None 7 82
Low dose (200-300 cGy) 4 36
Moderate dose (500 cGy) 8 40
High dose (1200 cGy) 33 92
VHD prophylaxis .02
CSA  MTX 48 186
CSA  MMF 3 56
All others 1 8
ype of graft .12
Peripheral blood 32 181
Bone marrow 20 69
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CNS Complications in Allogeneic Transplant Recipients 1375hylaxis (P  .02). No-risk factors were identiﬁed for
he development of CNS complications after 100 days
osttransplant (data not shown). Univariate analysis
id not identify any signiﬁcant risk factors associated
ith the development of PRES (data not shown).
ultivariate regression analysis identiﬁed female gen-
er (P  .03) and high-dose TBI (P  .0008) as
ndependent risk factors for CNS complications
ithin the ﬁrst 100 days posttransplant (Table 4).
At the onset of CNS events, 77% (n  17) of
atients with PRES and 75% (n 45) of patients with
ther CNS complications were receiving cyclospor-
ne. Nine percent (n  2) of patients with PRES and
3% (n  8) of patients with other CNS complica-
ions were receiving tacrolimus. Information on drug
ype and blood levels was unavailable for 2 patients
ith PRES and 5 patients with other CNS complica-
ions. One patient with PRES and 2 patients with
ther CNS complications were receiving neither cy-
losporine nor tacrolimus at complication onset.
ean cyclosporine levels (SD) were 299  116
g/mL and 243  170 ng/mL at the onset of PRES
nd other CNS complications, respectively (P  .25).
wenty-three percent (n  4) of patients with PRES
nd 9% (n  4) of patients with other CNS compli-
ations had calcineurin inhibitor levels above the tar-
et therapeutic range. At the onset of CNS complica-
ions, hypomagnasemia (0.6 mmol/L) was found in
able 3. (Continued)
Characteristics
P
Co
LA match
Identical family donor
Mismatched family donor
Matched unrelated donor
VA/TIA prior to transplant
Yes
No
eizures prior to transplant
Yes
No
ML indicates acute myeloid leukemia; MDS, myelodysplastic syn
leukemia; NHL, Non-Hodgkin’s lymphoma; CLL, chronic ly
high-dose ara-C; TBI, total body irradiation; GVHD, graft-ve
phenolate mofetil; HLA, human leukocyte antigen; CVA, cereb
CML (n 23), Ph ALL (n 9), AML (n 6), Ph biphenotyp
imatinib in combination with NOVE-HiDAC as part of a Phas
able 4. Multivariate Regression Analysis for CNS Complications with
Variable Comparis
ender Female versus male
BI in conditioning regimen None versus high dose (1200 c
Low/mod (200-500 cGy) versuI indicates conﬁdence interval; TBI, total-body irradiation.4% of patients with PRES and 9% (n 5) of patients
ith other CNS complications.
urvival
Survival at 1 year was signiﬁcantly reduced in
atients who developed CNS complications within
00 days of transplant compared to those who did not
28% [95% CI: 17-41] versus 72% [95% CI: 66-77],
 .0001) (Figure 3A). Of the 52 patients experienc-
ng CNS complications in the ﬁrst 100 days, 75% (n
9) died. The causes of death were GVHD (n  21),
nderlying disease (n  5), infections (n  3), RRT
n  6), and others (n  4). Ninety-one of 246 pa-
ients without CNS complications died of GVHD
n  23), underlying disease (n  34), infections (n 
2), RRT (n  8), and others (n  14). A signiﬁcantly
arger proportion of patients with CNS complications
n the ﬁrst 100 days posttransplant died of GVHD
hen compared to patients without CNS complica-
ions (P  .006).
There was a signiﬁcantly inferior 1-year survival in
atients with compared to those without PRES (27%
95% CI: 10-47] versus 67% [95% CI: 62-73], P 
0001) (Figure 3B). Causes of death were GVHD (n
1), underlying disease (n  1), RRT (n  1), and
thers (n  3). Among the 281 patients who did not
evelop PRES, 114 died. Causes of death were under-
s with CNS
tions (n  52)
Patients without CNS
Complications (n  250) P-Value
.28
34 190
6 20
12 40
.36
0 4
52 579
.17
2 3
50 247
; CML, chronic myelogenous leukemia; ALL, acute lymphocytic
ytic leukemia; AA, aplastic anemia; MF, myeloﬁbrosis; HiDAC,
st disease; CSA, cyclosporine; MTX, methotrexate; MMF, myco-
lar accident; TIA, transient ischemic attack.
leukemia (n 1), and CMML (n 1). The AML patients received
l for relapsed/refractory AML.
Days Posttransplant
Odds Ratio 95% CI P-Value
2.04 1.08-3.82 .03
0.22 0.09-0.52 .0008
dose (1200 cGy) 0.38 0.18-0.81atient
mplica
drome
mphoc
rsus-ho
rovascu
ic acutein 100
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Gy)
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D. Siegal et al.1376ying disease (n  38), GVHD (n  33), infections
n  15), RRT (n  13), and others (n  15). A
igniﬁcantly larger proportion of patients with PRES
ied as a result of GVHD than those without PRES
P  .01). Median time to death in PRES patients was
1 days (range: 3-377 days). For patients with mild,
oderate, and severe PRES, the mean number of days
o death (SD) was 213 191, 82 97, and 68 70,
espectively.
ISCUSSION
The cumulative incidence of CNS complications
igure 3. Kaplan-Meier plots of overall survival in patients with an
n comparison to their counterparts, survival at 1-year was signiﬁcan
ays posttransplant (28% versus 72%, P  .0001) (A), and PRES (nd PRES at days 100 and 365 was 18% and 23%, and i% and 7%, respectively, indicating they represent a
igniﬁcant clinical problem following aHSCT. The
isk was higher during the ﬁrst 100 days posttrans-
lant when 69% of CNS complications and 86% of
RES episodes occurred. Previous studies report a
ide variation of incidences of CNS complications in
HSCT recipients [1-11]. Some of these studies are
ifﬁcult to compare due to methodologic issues. Our
esults are similar to a prospective study describing the
0-day incidence of major CNS complications as 25%
1]. PRES has been reported in 7.2% and 5.5% of
HSCT patients receiving calcineurin inhibitors for
VHD prophylaxis [15,18]. However, only the crude
ut CNS complications (within 100 days posttransplant) and PRES.
uced in patients who developed CNS complications in the ﬁrst 100
rsus 67%, P  .0001) (B).d witho
tly redncidence of PRES was determined and competing
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yclosporine toxicity and CNS events as synonyms.
ur results are consistent with studies describing the
ncidence of severe cyclosporine neurotoxicity ranging
rom 4.2% to 9% [9,17,19]. A previous retrospective
tudy from the M.D. Anderson Hospital described the
rude incidence of PRES as 1.6% in aHSCT recipi-
nts receiving tacrolimus following aHSCT [34].
here are no comparative data available on the impact
f cyclosporine on CNS complications when com-
ared to tacrolimus. The lower incidence of PRES in
acrolimus-treated aHSCT recipients raises a possibil-
ty that there may be differences between cyclosporine
nd tacrolimus with regards to PRES development.
Female gender and high-dose TBI were identiﬁed
s independent risk factors for CNS complications
ithin the ﬁrst 100 days posttransplant. Gender has
ot been previously identiﬁed as a risk factor for CNS
omplications and we are unable to explain this ﬁnd-
ng. A previous study in pediatric patients also identi-
ed high-dose TBI as a risk factor for CNS compli-
ations [3]. In addition, TBI-containing regimens
ave been associated with a higher rate of cyclosporine
eurotoxicity in adult aHSCT recipients [18]. No
ifference in CNS complications was observed be-
ween patients treated with reduced or MIC condi-
ioning and those treated with chemotherapy or low-
ose TBI-based myeloblative regimens. We did not
dentify any risk factors related to PRES development.
nadequate power may have affected the ability to
etect statistically signiﬁcant risk factors. Further
tudies with a larger number of patients with PRES
re needed to identify risk factors.
There does not appear to be a correlation between
upratherapeutic calcineurin inhibitor levels and CNS
vents or PRES as only 23% of patients with PRES
nd 9% of patients with other CNS complications had
alcineurin inhibitor trough levels higher than the
herapeutic range at the onset of complications. This
s consistent with the lack of direct correlation be-
ween cyclosporine levels and seizures/cyclosporine
eurotoxicity described previously [17,35]. However,
t is possible that differences in neurotoxicity may be
elated to genetic differences in drug metabolism and
eeds further exploration in future studies [36]. Hy-
omagnesemia has been suggested as a risk factor for
yclosporine toxicity [37]. However, in our study, it
as present in only a small number of patients expe-
iencing PRES or other CNS events.
No modiﬁable risk factors for CNS complications
r PRES prior to AHSCT were identiﬁed in this
tudy. It is noteworthy that of 5 patients with a history
f seizures prior to transplant, 2 developed seizures.
lthough this is a limited number of patients, it may
e reasonable to avoid high-dose TBI in such patients.An important ﬁnding of this study was signiﬁ-
antly reduced survival of patients with CNS compli-
ations and PRES compared to those without [28%
ersus 72% (P  .0001) and 27% versus 67% (P 
0001), respectively]. Reduced 90-day survival has
een shown in aHSCT patients who develop neuro-
ogic complications compared with their counterparts
1]. A study of pediatric stem cell transplant recipients,
owever, showed no difference in overall survival be-
ween patients with and without neurologic complica-
ions [7]. Both autologous and allogeneic transplant
ecipients were included in this analysis. A lack of
ssociation between neurologic complications and
reatment-related mortality has also been described in
dult aHSCT recipients [2]. However, survival data
nd analysis were not presented in this report.
A signiﬁcantly larger number of patients with
NS complications in the ﬁrst 100 days and PRES
ied as a result of GVHD compared to patients with-
ut these complications. GVHD has been shown to
epresent the primary cause of death following cal-
ineurin inhibitor-induced neurotoxicity, but survival
as not compared to patients without neurotoxicity
15]. Signiﬁcant mortality due to GVHD may be re-
ated to discontinuation of calcineurin inhibitors re-
ulting in poor prevention of GVHD. Novel strategies
re needed for GVHD prevention in patients whose
osttransplant course is complicated by CNS events.
ncreased severity of PRES appears to be related to a
horter interval between PRES onset and death. How-
ver, these observations are derived from a small num-
er of patients, and should be interpreted with cau-
ion. Further studies are needed to clarify the
elationship between severity of PRES and clinical
utcomes.
In conclusion, CNS complications are a signiﬁcant
linical problem in the posttransplant period in
HSCT patients and are associated with increased risk
f death primarily due to GVHD. MR imaging can
rovide early diagnosis and follow-up to monitor
reatment changes. Novel strategies are needed in
hese patients for effective control of GVHD.
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